Marina Stanislav

1.7k total citations · 1 hit paper
20 papers, 601 citations indexed

About

Marina Stanislav is a scholar working on Rheumatology, Immunology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Marina Stanislav has authored 20 papers receiving a total of 601 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Rheumatology, 8 papers in Immunology and 6 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Marina Stanislav's work include Rheumatoid Arthritis Research and Therapies (12 papers), Systemic Lupus Erythematosus Research (6 papers) and Monoclonal and Polyclonal Antibodies Research (6 papers). Marina Stanislav is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (12 papers), Systemic Lupus Erythematosus Research (6 papers) and Monoclonal and Polyclonal Antibodies Research (6 papers). Marina Stanislav collaborates with scholars based in Russia, United States and Spain. Marina Stanislav's co-authors include Désirée van der Heijde, Roy Fleischmann, César Ramos-Remus, Sirel Gurbuz, Alberto Spindler, Tsutomu Takeuchi, Cristiano A. F. Zerbini, Michael Schiff, William L. Macias and Stephanie de Bono and has published in prestigious journals such as SHILAP Revista de lepidopterología, Annals of the Rheumatic Diseases and Lara D. Veeken.

In The Last Decade

Marina Stanislav

17 papers receiving 580 citations

Hit Papers

Baricitinib, Methotrexate, or Combination in Patients Wit... 2016 2026 2019 2022 2016 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease‐Modifying Antirheumatic Drug Treatment
    2016 309 citations Roy Fleischmann, Michael Schiff et al. Arthritis & Rheumatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Marina Stanislav Russia 9 430 192 179 126 113 20 601
Daniel Siri Argentina 4 517 1.2× 189 1.0× 253 1.4× 114 0.9× 86 0.8× 4 645
Nilzio A Da Silva Brazil 2 515 1.2× 209 1.1× 259 1.4× 108 0.9× 94 0.8× 4 672
M. Schiff United States 5 422 1.0× 180 0.9× 201 1.1× 116 0.9× 45 0.4× 10 656
Victoria Bejarano United Kingdom 9 469 1.1× 256 1.3× 197 1.1× 87 0.7× 48 0.4× 10 650
S Songcharoen United States 6 421 1.0× 141 0.7× 184 1.0× 123 1.0× 104 0.9× 7 654
D. van Schaardenburg Netherlands 9 628 1.5× 178 0.9× 149 0.8× 82 0.7× 50 0.4× 34 747
Regina Kurrasch United States 12 266 0.6× 188 1.0× 71 0.4× 77 0.6× 57 0.5× 21 534
Sheila Kelly United States 11 400 0.9× 220 1.1× 155 0.9× 61 0.5× 32 0.3× 17 553
L.E. Burgers Netherlands 16 617 1.4× 126 0.7× 202 1.1× 79 0.6× 34 0.3× 23 724
Laura Nuño Spain 16 562 1.3× 478 2.5× 117 0.7× 114 0.9× 59 0.5× 60 944

Countries citing papers authored by Marina Stanislav

Since Specialization
Citations

This map shows the geographic impact of Marina Stanislav's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marina Stanislav with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marina Stanislav more than expected).

Fields of papers citing papers by Marina Stanislav

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marina Stanislav. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marina Stanislav. The network helps show where Marina Stanislav may publish in the future.

Co-authorship network of co-authors of Marina Stanislav

This figure shows the co-authorship network connecting the top 25 collaborators of Marina Stanislav. A scholar is included among the top collaborators of Marina Stanislav based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marina Stanislav. Marina Stanislav is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Stanislav, Marina, Anjela Tzontcheva, Ruji Yao, et al.. (2023). Efficacy and safety of golimumab in patients with non-radiographic axial spondyloarthritis: a withdrawal and retreatment study (GO-BACK). Lara D. Veeken. 62(11). 3601–3609. 8 indexed citations
2.
Stanislav, Marina, et al.. (2020). Evaluation of safety and efficacy of Hylan G-F 20 (Synvisc-One®) in patients with knee osteoarthritis in clinical practice. N N Priorov Journal of Traumatology and Orthopedics. 27(2). 36–44. 1 indexed citations
3.
Genovese, Mark C., Désirée van der Heijde, Yong Lin, et al.. (2019). Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment. RMD Open. 5(2). e000887–e000887. 29 indexed citations
4.
5.
Benedetti, Fabrizio De, Inmaculada Calvo Penadés, Alexey Maschan, et al.. (2019). FRI0549 SARILUMAB, A HUMAN MONOCLONAL ANTIBODY TO THE INTERLEUKIN-6 (IL-6) RECEPTOR, IN POLYARTICULAR-COURSE JUVENILE IDIOPATHIC ARTHRITIS (PCJIA): A 12-WEEK MULTINATIONAL OPEN-LABEL DOSE-FINDING STUDY. Annals of the Rheumatic Diseases. 78. 969–970. 5 indexed citations
6.
Curtis, Jeffrey R., Yong Lin, Karthinathan Thangavelu, et al.. (2019). FRI0081 WITHDRAWAL OF CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN THE SARILUMAB OPEN-LABEL EXTEND STUDY: EFFICACY AND SAFETY ANALYSIS. Annals of the Rheumatic Diseases. 78. 702–703. 1 indexed citations
7.
Fleischmann, Roy, Mark C. Genovese, Yong Lin, et al.. (2019). Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years’ follow-up. Lara D. Veeken. 59(2). 292–302. 55 indexed citations
8.
9.
Kivitz, Alan, Hubert van Hoogstraten, Sheldon Wang, et al.. (2017). Usability and Patient Preference Phase 3 Study of the Sarilumab Pen in Patients with Active Moderate-to-Severe Rheumatoid Arthritis. Rheumatology and Therapy. 5(1). 231–242. 21 indexed citations
10.
11.
Hsu, Vivien, Christopher P. Denton, Robyn T. Domsic, et al.. (2017). Pomalidomide in Patients with Interstitial Lung Disease due to Systemic Sclerosis: A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study. The Journal of Rheumatology. 45(3). 405–410. 29 indexed citations
12.
Fleischmann, Roy, Michael Schiff, Désirée van der Heijde, et al.. (2016). Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease‐Modifying Antirheumatic Drug Treatment. Arthritis & Rheumatology. 69(3). 506–517. 309 indexed citations breakdown →
13.
Stanislav, Marina, et al.. (2013). Ustekinumab is a new drug to treat psoriasis and psoriatic arthritis. SHILAP Revista de lepidopterología. 0(2). 170–170.
14.
Nasonov, E L, et al.. (2013). INTERLEUKIN-17 IS A NEW TARGET FOR ANTI-CYTOKINE THERAPY OF IMMUNE INFLAMMATORY RHEUMATIC DISEASES. SHILAP Revista de lepidopterología. 51(5). 545–545. 7 indexed citations
15.
Каратеев, Д. Е., et al.. (2012). New treatment possibilities for rheumatoid arthritis: the Russian experience in using certolizumab pegol. SHILAP Revista de lepidopterología. 0(2). 14–14. 1 indexed citations
16.
Nasonov, E L, et al.. (2012). Prospects of pharmacotherapy for rheumatoid arthritis: Monoclonal antibodies. SHILAP Revista de lepidopterología. 0(3). 75–75.
17.
Nasonov, E L, et al.. (2012). New aspects of pharmacotherapy for rheumatoid arthritis: small molecule inhibitors. SHILAP Revista de lepidopterología. 0(2). 66–66. 2 indexed citations
18.
Насонов, Е. Л., et al.. (2012). BELIMUMAB: ADVANCES IN DRUG THERAPY FOR SYSTEMIC LUPUS ERYTHEMATOSUS. SHILAP Revista de lepidopterología. 0(5). 13–13. 9 indexed citations
19.
Насонов, Е. Л., Marina Stanislav, V. V. Yakusevich, et al.. (2009). An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus. Lupus. 18(6). 547–555. 82 indexed citations
20.
Stanislav, Marina, et al.. (2002). [Hypocomplementary urticarial vasculitis with the mitral valve affection and complement-fixed antibodies to the myocardial antigens].. PubMed. 74(5). 47–52. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Daniel Siri Breakdown of academic impact, for papers by Nilzio A Da Silva Breakdown of academic impact, for papers by M. Schiff Breakdown of academic impact, for papers by Victoria Bejarano Breakdown of academic impact, for papers by S Songcharoen Breakdown of academic impact, for papers by D. van Schaardenburg Breakdown of academic impact, for papers by Regina Kurrasch Breakdown of academic impact, for papers by Sheila Kelly Breakdown of academic impact, for papers by L.E. Burgers Breakdown of academic impact, for papers by Laura Nuño
Rankless by CCL
2026